Tirzepatide (mounjaro) 5mg 10mg 15mg ogbugba

nkowa nkenke:

Aha: Tirzepatide

Nkọwa: 5mg / vial * 10vials / igbe 10mg / vial * 10vial / igbe 15mg / vial * 10vial / igbe.

Ahịa: 5mg USD110/igbe 10mg USD220/igbe 15mg USD330/igbe

Ụlọ nyocha: Lianfu Bio

MOQ: 1 igbe

Zitere anyị email

Nkọwa ngwaahịa

Tirzepatide

Tirzepatide bụ nyocha otu ugboro n'izu, insulinotropic polypeptide glucose na-adabere na glucose na glucagon dị ka peptide-1 agonist nke na-ejikọta omume nke incretins abụọ n'ime otu molekul.

Tirzepatide na-eṅomi Hormones eke na-akwalite inwe mmetụta zuru oke
Tirzepatide na-arụ ọrụ site n'iṅomi GLP-1 na GIP hormones nke eriri afọ na-ezobe na ya mgbe erichara nri, nke na-akpali mmepụta insulin.Ọ na-ebelatakwa agụụ site n'ibelata oge ọ na-ewe afọ iji tọgbọrọ chakoo na imekọrịta ihe na mpaghara ụbụrụ nke nwere ndị na-anabata GLP-1 iji gosi satiety.

Tirzepatide bụ ọgwụ ọhụrụ nke FDA kwadoro maka ọgwụgwọ ụdị ọrịa shuga mellitus 2.N'iburu n'uche njirimara dị oke ibu ya,tirzepatidea ga-eji anya-aha maka ọgwụgwọ oke ibu.Ọ na-arụ ọrụ dị ka agonist GLP-1 dual na GIP agonist iji bulie uru yiri nke a na-ahụ na ọgwụ GLP-1 dị ka semaglutide.A na-eme ya ugbu a dị ka ọgwụ ọrịa shuga nke abụọ, dị ka ọgwụ GLP-1, ma na-enye ya dị ka injectable subcutaneous otu ugboro n'izu.

Tirzepatide bụ onye nnabata insulinotropic polypeptide (GIP) na-anabata glucose na glucagon-dị ka peptide-1 (GLP-1) recepto agonist, nke FDA kwadoro maka ọgwụgwọ ụdị ọrịa shuga mellitus 2.Ọ dị mkpa ịmara na anabataghị tirzepatide maka ọgwụgwọ ụdị-1 ọrịa shuga mellitus ma amụbeghị ya na ndị ọrịa nwere pancreatitis.Tirzepatide bụ onye na-anabata GIP na onye na-anabata GLP-1, na-eduga na njikwa glycemic ka mma na ụdị ọrịa shuga 2 na mbelata ibu dị ukwuu.

FDA kwadoro Tirzepatide na Mee 2022. A pụkwara iji Tirzepatide mee ihe maka ọgwụgwọ oke ibu.A na-eme ya ugbu a dị ka ọgwụ ọrịa shuga nke abụọ, dị ka ọgwụ GLP-1 dị ka semaglutide.Ọ bụ ọgwụ ịgba ọgwụ mgbochi subcutaneous otu ugboro n'izu na-abawanye dose.

Data ụlọ ọgwụ dị ugbu a egosila na tirzepatide dị elu karịa placebo n'ịkwalite ọkwa hemoglobin A1C.Nnyocha ụlọ ọgwụ SURPASS-5 gosipụtara mbelata -2.11% na ọkwa hemoglobin A1C na 5mg kwa izu dosing, ma e jiri ya tụnyere -0.86% na placebo.N'ihe kachasị elu nke 15 mg kwa izu, tirzepatide mere ka mbelata -2.34% na hemoglobin A1C.E gosipụtara nke a ihe karịrị izu iri anọ.A hụrụ mbelata ịdị arọ nke 5.4 n'arọ site na 5mg nke tirzepatide dosing, na mbelata 10.5 n'arọ na-eji 15 mg dosing.Mmekọrịta a na-adabere na dose na ọnwụ dị arọ yiri semaglutide, ọgwụ GLP-1 a na-ejikarị eme ihe maka njikwa ọnwụ.

N'otu aka ahụ, egosiri tirzepatide na-arụ ọrụ n'otu aka ahụ na ọgwụ GLP-1 mana ọ na-arụ ọrụ nke ọma.N'iburu n'uche njirimara ọnwụ ya na enweghị nsị imeju, o yikarịrị ka ọ ga-ekere òkè na-apụtaghị ìhè na ọgwụgwọ ọrịa imeju na-adịghị egbu egbu (NAFLD).